The article reports that oncologic drug pricing is being transformed with greater value in mind at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021. Topics include how the current rebate system supports higher drug costs, balancing new interventions with profits, and the implications of drug price negotiations being considered in Congress; and change the amount of investment that goes into the throughput and research and development cost.